ABCG2 and cancer: We found that TMP195 reversed ABCG2-mediated resistance to mitoxantrone and topotecan to a comparable level as that of Ko143, an ABCG2 benchmark inhibitor, in S1-M1-80 and H460-MX20 cancer cells.